The invention discloses an application of long-chain non-coding RNA TRALR. The present invention uses lncRNA sequencing to find that lncRNA TRALR is abnormally highly expressed in temozolomide-resistant glioma cell lines, and specifically interfering with the expression of lncRNA TRALR can significantly inhibit BMI1, up-regulate p21 levels, and promote cell cycle arrest and aging , increase the sensitivity of glioma temozolomide. Therefore, the reagents for detecting the expression of lncRNA TRALR can be used to prepare preparations for the diagnosis, prognosis, or sensitivity detection of glioma patients, providing a powerful tool for the diagnosis, prognosis, and chemotherapy sensitivity prediction of glioma patients. Based on molecular biology, it has far-reaching clinical significance and important promotion and application prospects.